Abstract Details

Title Sleep Patterns in Patients with Postural Orthostatic Tachycardia Syndrome

Topic Autonomic Disorders

Presentation(s) P03 - (-)

Poster/Presentation
Number 042

Objective

Background BACKGROUND: POTS is defined as symptomatic orthostatic intolerance associated with a heart rate increase of 30 bpm (or exceeding 120 bpm) within the first 10 minutes of standing or upright tilt, not associated with other chronic debilitating conditions or medications known to diminish vascular or autonomic tone. Recent data shows that patients with POTS suffer from fatigue, non-restorative sleep and sleepiness. There is limited literature on objective evidence of sleep dysfunction in this population. Here we present initial objective data in a population of patients with POTS with sleep complaints.

Design/Methods DESIGN/METHODS: Patients diagnosed with POTS (n=7) with reported daytime sleepiness were evaluated by actigraphy (n=4; women=100%; mean age 45.5 years; range 25-56) and polysomnography (n=6; women=100%; mean age= 34.3; range 25-55). One patient was excluded from polysomnography data due to the diagnosis of mild obstructive sleep apnea. Three patients declined actigraphy. Measurements included number of nocturnal awakenings as well as the average hours of sleep, sleep efficiency and apnea-hyponea index .

Results RESULTS: All patients showed an increase in the average number of nocturnal awakenings (2.41 per night, range 1.8-3.25) with normal sleep durations (7.45 hours, range 6.5-8.7). Sleep efficiency was reduced (62.02%, range=47.6-78.1) with prolonged REM latencies (229.8minutes, range 127.5-404.5) despite a normal AHI (0.46, range 0-1.6).

Conclusions CONCLUSIONS: Patients with POTS demonstrate an abnormal increase in nocturnal awakenings and a decrease in sleep efficiency, despite normal sleep durations. This may account for complaints of daytime somnolence in this population. Further investigation into sleep dysfunction is required given our limited sample size.

Authors/Disclosures
Okeanis Vaou, MD, FAAN (UT San Antonio) PRESENTER	Dr. Vaou has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ABBVIE. Dr. Vaou has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Vaou has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic . Dr. Vaou has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for medtronic. An immediate family member of Dr. Vaou has stock in SAGE. The institution of Dr. Vaou has received research support from Medtronic.
Gavin Giovannoni, MD (QMUL)	Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck KGaA. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche-Genentech. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Moderna. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Astoria Biologica. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zenas. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medscape.
Andrew J. Westwood, MD, FAAN	Dr. Westwood has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Healthcare Business Solutions UK. Dr. Westwood has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda.
Yelena G. Pyatkevich, MD (Takeda Pharmaceutical)	Dr. Pyatkevich has received personal compensation for serving as an employee of Takeda. Dr. Pyatkevich has stock in Takeda.
Sanford H. Auerbach, MD, FAAN (Boston University Medical Center)	Dr. Auerbach has nothing to disclose.
Anna D. Hohler, MD, FAAN (Steward SEMC)	Dr. Hohler has nothing to disclose.

��ɫ��

��ɫ��